These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37984358)

  • 1. Recommendations on the use of COVID-19 Convalescent Plasma to Treat Immunocompromised Patients.
    Franchini M; Casadevall A; Senefeld JW; Joyner MJ; Sullivan DJ; Focosi D
    Semin Thromb Hemost; 2024 Jun; 50(4):648-653. PubMed ID: 37984358
    [No Abstract]   [Full Text] [Related]  

  • 2. Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.
    Ripoll JG; Tulledge-Scheitel SM; Stephenson AA; Ford S; Pike ML; Gorman EK; Hanson SN; Juskewitch JE; Miller AJ; Zaremba S; Ovrom EA; Razonable RR; Ganesh R; Hurt RT; Fischer EN; Derr AN; Eberle MR; Larsen JJ; Carney CM; Theel ES; Parikh SA; Kay NE; Joyner MJ; Senefeld JW
    mBio; 2024 May; 15(5):e0040024. PubMed ID: 38602414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent blood plasma (CBP) donated by recovered COVID-19 patients - A comment.
    Lung T; Sakem B; Risch M; Nydegger U
    Transfus Apher Sci; 2021 Jun; 60(3):103108. PubMed ID: 33678561
    [No Abstract]   [Full Text] [Related]  

  • 4. [COVID-19: Still a place for the convalescent plasma? Focus on the immunocompromised patients].
    Richier Q; Hueso T; Tiberghien P; Lacombe K
    Rev Med Interne; 2023 Sep; 44(9):467-471. PubMed ID: 37689526
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
    Focosi D; Franchini M
    Expert Rev Vaccines; 2022 Jul; 21(7):877-884. PubMed ID: 34015243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
    Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
    Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies.
    Janssen M; Leo A; Wolf C; Stenzinger M; Bartenschlager M; Brandt J; Sauer S; Schmitt M; Dreger P; Schlenk RF; Denkinger CM; Müller-Tidow C
    Int J Cancer; 2024 Aug; 155(4):618-626. PubMed ID: 38721724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thinking more about therapy with convalescent plasma for COVID-19 patients.
    Han G; Zhou YH
    Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
    Kenig A; Ishay Y; Kharouf F; Rubin L
    Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
    Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
    Pau AK; Aberg J; Baker J; Belperio PS; Coopersmith C; Crew P; Grund B; Gulick RM; Harrison C; Kim A; Lane HC; Masur H; Sheikh V; Singh K; Yazdany J; Tebas P;
    Ann Intern Med; 2021 Jan; 174(1):93-95. PubMed ID: 32976026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
    Front Immunol; 2021; 12():613502. PubMed ID: 33968017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.
    Prus K; Alquist CR; Cancelas JA; Oh D
    Transfusion; 2021 Feb; 61(2):651-654. PubMed ID: 33616966
    [No Abstract]   [Full Text] [Related]  

  • 16. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
    Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
    [No Abstract]   [Full Text] [Related]  

  • 17. Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019.
    Hartog N; Holsworth A; Rajasekaran S
    Ann Allergy Asthma Immunol; 2021 Feb; 126(2):122-123. PubMed ID: 33161152
    [No Abstract]   [Full Text] [Related]  

  • 18. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
    Richier Q; De Valence B; Chopin D; Gras E; Levi LI; Abi Aad Y; Pacanowski J; Meynard JL; Plaçais L; Fey D; Couture P; Martin-Blondel G; Pestre V; Woessner J; Ancellin S; Weyrich P; Carpentier B; Idri S; Tiberghien P; Surgers L; Hueso T; Lacombe K
    Influenza Other Respir Viruses; 2024 Mar; 18(3):e13272. PubMed ID: 38501337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
    Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
    Front Immunol; 2021; 12():711915. PubMed ID: 34276706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upper age limits for convalescent plasma donation and treatment of COVID-19 patients: A further marker of ageism.
    Fedecostante M; O'Neill D; Pierri F; Carrieri B; Lattanzio F; Cherubini A
    Transfusion; 2021 Sep; 61(9):2799-2800. PubMed ID: 34227110
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.